- Home
- VRTX
as 08-01-2025 4:00pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Upcoming Earnings Alert:
Get ready for potential market movements as Vertex Pharmaceuticals Incorporated VRTX prepares to release earnings report on 04 Aug 2025.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 115.6B | IPO Year: | 1991 |
| Target Price: | $509.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 08-04-2025 |
| Revenue: | $11,099,700,000 | Revenue Growth: | 8.98% |
| Revenue Growth (this year): | 10.43% | Revenue Growth (next year): | 10.81% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | May 15 '25 | Sell | $424.69 | 52 | $22,083.88 | 23,281 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Zacks
3 days ago
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Zacks
3 days ago
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Zacks
4 days ago
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks
4 days ago
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Zacks
4 days ago
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
PR Newswire
4 days ago
LEAD3R Launches 2025 Healthy Team Summit, Sponsored by The Future of Teamwork Podcast
Zacks
5 days ago
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.